Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company focused on hearing and balance solutions, announced that CEO Laurence Reid will participate in a fireside chat during the H.C. Wainwright Global Investment Conference. The chat will be available on-demand starting May 24, 2022, at 7:00 a.m. E.T. Interested viewers can access the webcast in the Investors section of the Decibel Therapeutics website. An archived version will be available for 90 days following the event.

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T.

A webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200

Media Contact:
Chris Railey
Ten Bridge Communications
Chris@tenbridgecommunications.com
617-834-0936

FAQ

When will Decibel Therapeutics' CEO participate in the H.C. Wainwright Global Investment Conference?

Laurence Reid, CEO of Decibel Therapeutics, will participate in the conference on May 24, 2022.

How can investors watch the Decibel Therapeutics fireside chat?

The fireside chat can be accessed on-demand in the Investors section of the Decibel Therapeutics website starting May 24, 2022, at 7:00 a.m. E.T.

What is the focus of Decibel Therapeutics?

Decibel Therapeutics is dedicated to discovering and developing treatments for hearing and balance disorders.

How long will the webcast of the fireside chat be available?

An archived replay of the webcast will be available for approximately 90 days after the event.

What is Decibel Therapeutics' lead product candidate?

The lead product candidate of Decibel Therapeutics is DB-OTO, aimed at treating congenital, monogenic hearing loss.